Stockscreener 앱 받기
50.67
2.76%
1.36
시간 외 거래:
50.67
전일 마감가:
$49.31
열려 있는:
$49.35
하루 거래량:
1.12M
Relative Volume:
0.79
시가총액:
$7.32B
수익:
-
순이익/손실:
$-946.53M
주가수익비율:
-7.2735
EPS:
-6.9664
순현금흐름:
$-814.94M
1주 성능:
+11.56%
1개월 성능:
-3.28%
6개월 성능:
+17.67%
1년 성능:
+50.62%
1일 변동 폭
$49.35
$51.91
1주일 범위
$45.30
$51.91
52주 변동 폭
$29.08
$65.00
백스사이트 Stock (PCVX) Company Profile
명칭
Vaxcyte Inc
전화
650-837-0111
주소
825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS, CA
Compare PCVX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PCVX
Vaxcyte Inc
|
50.67 | 7.16B | 0 | -946.53M | -814.94M | -6.9664 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
백스사이트 Stock (PCVX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-07 | 재확인 | Needham | Buy |
| 2025-09-12 | 개시 | Goldman | Neutral |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-12-20 | 개시 | Goldman | Buy |
| 2023-12-07 | 개시 | Mizuho | Buy |
| 2023-04-18 | 개시 | TD Cowen | Outperform |
| 2023-01-03 | 재확인 | Needham | Buy |
| 2022-12-15 | 개시 | Guggenheim | Buy |
| 2022-11-17 | 개시 | BTIG Research | Buy |
| 2021-12-29 | 재개 | Jefferies | Buy |
| 2021-06-24 | 재개 | Jefferies | Buy |
| 2020-07-07 | 개시 | BofA Securities | Buy |
| 2020-07-07 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-07-07 | 개시 | Needham | Buy |
모두보기
백스사이트 주식(PCVX)의 최신 뉴스
Vaxcyte (PCVX) AGM 2026 Summary - Quartr
PCVX: All proposals passed with strong support and no shareholder questions were raised - TradingView
PCVX: All board proposals passed with a strong quorum and no shareholder questions raised - TradingView
Rep. Gilbert Ray Cisneros, Jr. Purchases Shares of Vaxcyte, Inc. (NASDAQ:PCVX) - MarketBeat
TD Asset Management Inc Cuts Stock Holdings in Vaxcyte, Inc. $PCVX - MarketBeat
Vaxcyte, Inc. (PCVX) Stock Analysis: A Biotech With A Promising 130% Upside Potential - DirectorsTalk Interviews
Norges Bank Invests $56.70 Million in Vaxcyte, Inc. $PCVX - MarketBeat
Average basic shares outstanding of Vaxcyte, Inc. – XETR:5VA - TradingView
Net current asset value per share of Vaxcyte, Inc. – XETR:5VA - TradingView
Total assets of Vaxcyte, Inc. – XETR:5VA - TradingView
EBIT per share of Vaxcyte, Inc. – XETR:5VA - TradingView
Vaxcyte, Inc. Balance Sheet – XETR:5VA - TradingView
Vaxcyte, Inc. Statistics – XETR:5VA - TradingView
Vaxcyte, Inc. Dividends – XETR:5VA - TradingView
Discipline and Rules-Based Execution in PCVX Response - Stock Traders Daily
Westfield Capital Management Co. LP Lowers Position in Vaxcyte, Inc. $PCVX - MarketBeat
PCVX News | VAXCYTE INC (NASDAQ:PCVX) - ChartMill
Does Vaxcyte’s First-in-Human Group A Strep Trial Reshape The Bull Case For Vaxcyte (PCVX)? - simplywall.st
Analysts Offer Insights on Healthcare Companies: Repligen (RGEN), Vaxcyte (PCVX) and BeOne Medicines (ONC) - The Globe and Mail
Insider Sell Alert: Jim Wassil Sells Shares of Vaxcyte Inc (PCVX) - GuruFocus
Vaxcyte COO Jim Wassil sells $111k in PCVX stock - Investing.com UK
Vaxcyte COO Jim Wassil sells $111k in PCVX stock By Investing.com - Investing.com India
COO of Vaxcyte (NASDAQ: PCVX) sells 2,250 shares in pre-set plan - Stock Titan
Mizuho Securities Maintains Vaxcyte(PCVX.US) With Buy Rating, Maintains Target Price $163 - Moomoo
Vaxcyte (PCVX) Takes First Steps in Human Vaccine Trials - GuruFocus
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults - Investing News Network
Vaxcyte Doses First Participant In Phase 1 Study Evaluating Vax-A1 For The Prevention Of Disease Caused By Group A Streptococcus In Healthy Adults - TradingView
Vaxcyte Begins Phase 1 Clinical Trial for Group A Streptococcus Vaccine Candidate VAX-A1 - geneonline.com
Vaxcyte doses first participant in group A strep vaccine trial - Investing.com
Vaxcyte doses first participant in group A strep vaccine trial By Investing.com - Investing.com Australia
Vaxcyte Doses First Participant in Phase 1 Study Evaluating - GlobeNewswire
Vaxcyte Inc stock (US92242T1016): Q1 2026 results and outlook ahead of next earnings date - AD HOC NEWS
PCVX insider sales disclosed: James Wassil sold 11,895 shares (PCVX) - Stock Titan
Vaxcyte, Inc. (PCVX) Stock Analysis: Exploring a Promising 112% Upside in the Biotech Sector - DirectorsTalk Interviews
Why Vaxcyte (PCVX) Is Up 8.7% After Completing Key VAX-31 Phase 3 Trial Enrollments - Yahoo Finance
Vaxcyte Inc stock (US92242T1016): shares steady as Phase 3 pneumonia vaccine program advances - AD HOC NEWS
Assessing Vaxcyte (PCVX) Valuation After Mixed Short And Long Term Share Price Moves - simplywall.st
Vaxcyte (PCVX) Completes Enrollment for Phase 3 VAX-31 Clinical Trials - Yahoo Finance
Vaxcyte Inc. (PCVX) Slips 1.4% as Shares Test Key Support ZoneMA Cross Alert - The Legal Advocate
Top 3 Health Care Stocks You'll Regret Missing In MayVaxcyte (NASDAQ:PCVX), Universal Health Services - Benzinga
Behavioral Patterns of PCVX and Institutional Flows - Stock Traders Daily
Vaxcyte, Inc. (PCVX) Stock Analysis: Unpacking a 130% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Vaxcyte stock (US92242T1016): clinical-stage vaccine developer draws attention after recent capital - AD HOC NEWS
Vaxcyte (PCVX) slips 3.8% as investors digest recent ownership filings and cash-burn outlook - Quiver Quantitative
Why Vaxcyte (PCVX) Is Down 9.7% After Steeper Q1 Losses And Accelerated R&D Spending - simplywall.st
Pfizer Expands Pneumococcal Vaccine Push With New Programs - Benzinga
Vaxcyte, Inc. (PCVX) Stock Analysis: Biotech Innovator With Over 100% Upside Potential - DirectorsTalk Interviews
Vaxcyte Inc stock (US92242T1016): fresh data from pneumococcal vaccine program keeps biotech in focu - AD HOC NEWS
Vaxcyte stock (US92242T1016): Pneumococcal vaccine data keeps investors focused - AD HOC NEWS
RA Capital reports 12.97M shares in Vaxcyte (NASDAQ: PCVX) - Stock Titan
Janus Henderson (PCVX) discloses 16.6M shares, 11.5% ownership - Stock Titan
백스사이트 (PCVX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.60%
0.94%
자본화:
|
볼륨(24시간):